Aurobindo Pharma Limited — Updates, 06-02-2025: Press Release

Aurobindo Pharma Limited reported consolidated financial results for the quarter ended December 31, 2024. Revenue from operations grew by 8.5% year-on-year to ₹7,979 Cr, with a diverse performance across its business segments. Notably, revenue from Europe surged by 22.7% to ₹2,121 Cr, while growth markets saw an impressive increase of 39.3% to ₹873 Cr. However, US formulations revenue dipped by 2.3% year-on-year to ₹3,671 Cr, attributed primarily to reduced transient product sales. The company generated an EBITDA before R&D of ₹2,056 Cr, yielding a margin of 25.8%. Despite a decline in net profit to ₹846 Cr, Aurobindo's commitment to expanding its manufacturing capabilities and enhancing its specialty and injectable business signals a positive outlook. The successful approval of eight ANDAs from the USFDA further underlines the company’s growth trajectory and upcoming product launches, suggesting potential growth opportunities for investors.